Evaluating Patient Satisfaction in Osteoarthritis Treatment
Author Information
Author(s): Dougados Maxime, Moore Alan, Yu Shaohua, Gitton Xavier
Primary Institution: Hôpital Cochin, Paris, France
Hypothesis
Does the Patient Acceptable Symptom State (PASS) provide a meaningful measure of treatment satisfaction in patients with osteoarthritis?
Conclusion
A high proportion of patients treated with lumiracoxib or celecoxib reported an acceptable symptom state after 13 weeks.
Supporting Evidence
- 43.3% of patients on lumiracoxib considered their state satisfactory at week 13.
- Patients on celecoxib also reported high satisfaction rates.
- Statistical significance was observed in treatment effects compared to placebo.
Takeaway
This study shows that many patients with knee pain felt better after taking specific medications for 13 weeks.
Methodology
Pooled analysis of two multicentre, double-blind, placebo-controlled studies over 13 weeks.
Potential Biases
Potential bias due to funding from Novartis, the manufacturer of the drugs studied.
Limitations
The study only included patients with knee osteoarthritis and may not be generalizable to other conditions.
Participant Demographics
{"mean_age":61.5,"gender_distribution":{"female_percentage":65.8,"male_percentage":34.2},"race_distribution":{"Caucasian_percentage":94.3,"Black_African_American_percentage":2.5}}
Statistical Information
P-Value
p<0.001
Confidence Interval
95% CI for NNTs provided
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website